Besides developing antibiotic resistance testing for gonorrhea, SpeeDx is also conducting multi-site clinical trials for the ResistancePlus MG test (not currently available for sale in the US).
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe.
SpeeDx specialises in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
Pty Ltd, Eveleigh, Sydney, New South Wales, Australia (E.
's test has received a CE mark and is approved for use across Europe.
The vehicle metrics (LaneX, SpeedX) are also larger for those tasks.
* Vehicle metrics: standard deviation of lane position (SDLP) - a continuous measure of lane keeping during the task; speed difference (SpeedX) - the difference of maximum and minimum speed during task.
SpeedX - Number of times more than 5 mph above or below instructed speed of 40 mph
Rubin, M.D., Ph.D., on the SpeeDx board of directors.
The flagship test from SpeeDx, ResistancePlus MG - detecting the sexually transmitted infection Mycoplasma genitalium, also known as Mgen or MG, and genetic markers linked to macrolide antibiotic resistance is currently in clinical trials in preparation for submission to the US Federal Drug Administration later this year.
- Australia-based molecular diagnostics company SpeeDx Pty, Ltd has inked an agreement with molecular diagnostics company Cepheid to manufacture their ResistancePlus tests for use on the GeneXpert System, the companies said.
The SpeeDx ResistancePlus MG assay is CE marked for sale in Europe and TGA approved for sale in Australia.